Frontage Laboratories, Inc., part of Frontage Holdings Corporation, has expanded its capabilities with the launch of a new Contract Research, Development, and Manufacturing Organization (CRDMO) facility in Exton, Pennsylvania. This state-of-the-art, 46,300-square-foot Good Manufacturing Practice $(GMP.UK)$ facility enhances Frontage's service offerings in drug substance synthesis, DMPK, safety & toxicology studies, bioanalysis, and clinical trial support. The facility features nine GMP suites tailored to diverse manufacturing needs, including high-potent, aseptic, and non-sterile suites, and is equipped to handle a variety of pharmaceutical forms such as injectables, tablets, and nasal preparations. The expansion underscores Frontage's commitment to accelerating pharmaceutical and biotech innovation by providing a comprehensive, one-stop-shop solution for clinical supplies.